Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma [Yahoo! Finance]
Delcath Systems, Inc. (DCTH)
US:NASDAQ Investor Relations:
delcath.com/investors
Company Research
Source: Yahoo! Finance
oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a narrative review by leading interventional radiologists and oncologists from multiple institutions. The review, titled "Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion," was published in the Journal of Vascular and Interventional Radiology (JVIR) and provides a comprehensive overview of percutaneous hepatic perfusion (PHP) with melphalan using Delcath's HEPZATO KIT™. The article highlights PHP's rationale, technique, patient selection, clinical outcomes, and future research directions, emphasizing its role as an FDA-approved liver-directed therapy for unresectable hepatic metastases from uveal melanoma (UM) with limited extrahepatic disease. "The publication of this expert narrative review in JVIR features the growing clinical evidence and consensus supporting the use of PHP as a key treatment option for patients with liver-dom
Show less
Read more
Impact Snapshot
Event Time:
DCTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting Delcath Systems, Inc. news events
Weekly update
A roundup of the hottest topics
DCTH
News
- Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire
- Returns On Capital Are Showing Encouraging Signs At Delcath Systems (NASDAQ:DCTH) [Yahoo! Finance]Yahoo! Finance
- Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade [Seeking Alpha]Seeking Alpha
- Delcath Systems (NASDAQ:DCTH) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
DCTH
Earnings
- 11/4/25 - In-Line
DCTH
Analyst Actions
- 1/9/26 - HC Wainwright
DCTH
Sec Filings
- 1/12/26 - Form 8-K
- 11/25/25 - Form 4
- 11/20/25 - Form 8-K
- DCTH's page on the SEC website